Combo Therapy Kicks Urate Target Goals

By Mardi Chapman via the Limbic, 2019

The use of combined xanthine oxidase inhibitors (febuxostat) with a uricosuric agent (lesinurad) has shown long term safety and efficacy in patients with tophaceous gout in a trial involving Australian centres.

In a two year follow up study, febuxostat and lesinurad were effective in lowering serum urate levels, reducing gout flares and decreasing the size and number of tophi, without comprising renal safety.

A 12-month extension of the CRYSTAL study, which first compared combination therapy with febuxostat alone, has also confirmed there were no new adverse events in a second year of combination therapy.

Click here, to read the full Limbic article

Click here, to view the CRYSTAL extension study